Mirum Pharmaceuticals, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024. The company achieved $336.4 million in net product sales for the full year 2024, with Q4 2024 net product sales reaching $99.430 million, a 43% increase from $69.554 million in Q4 2023.
The company reaffirmed its expected global net product sales guidance for 2025, projecting $420 million to $435 million. Mirum also reported a net loss of $23.790 million for Q4 2024, an improvement from a net loss of $35.659 million in Q4 2023, and a full-year 2024 net loss of $87.942 million, significantly reduced from $163.415 million in 2023.
Mirum provided updates on its pipeline, stating that the VISTAS study of volixibat in primary sclerosing cholangitis is expected to complete enrollment in the second half of 2025, with topline data anticipated in 2026. The recent FDA approval of CTEXLI for cerebrotendinous xanthomatosis was also highlighted as a key achievement.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.